Ophelia vs Idexx Laboratories
Side-by-side comparison of AI visibility scores, market position, and capabilities
Telehealth opioid use disorder treatment with buprenorphine prescribing; removing geographic barriers to MAT for patients in 20+ states through online clinical visits.
About
Ophelia is a telehealth platform specializing in medication-assisted treatment (MAT) for opioid use disorder, providing access to buprenorphine (Suboxone) through online consultations and prescription management for patients across the United States. Founded in 2019 and headquartered in New York City, Ophelia addresses the severe treatment access gap in opioid addiction care — where millions of Americans with opioid use disorder cannot access MAT due to provider shortages, geographic barriers, stigma, or cost.
Veterinary diagnostics leader with $3.81B FY2024 revenue; 130,000+ analyzer installed base; AI-powered inVue Dx digital cytology; VetConnect data platform; pet humanization tailwind.
About
IDEXX Laboratories is the global leader in veterinary diagnostics and information technology for companion animal healthcare, founded in 1983 by David Shaw in Westbrook, Maine, where it remains headquartered. The company trades on Nasdaq (IDXX) and reported $3.81 billion in revenues for FY2024, maintaining its dominant position in point-of-care veterinary diagnostics through an installed base of over 130,000 Catalyst chemistry analyzers, ProCyte hematology systems, and SNAP rapid assay devices deployed in veterinary clinics worldwide. CEO Jay Mazelsky has continued IDEXX's expansion into AI-powered diagnostics and digital pathology, building on over four decades of veterinary-specific product development.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.